Market Overview:
The global prostaglandin analogs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of glaucoma, rising awareness about glaucoma and its treatment options, and the launch of new products. Based on type, the global prostaglandin analogs market is segmented into Xalatan (latanoprost), Travatan (travoprost), Lumigan (bimatoprost), and Tafluprost. Of these, Xalatan held the largest share of the global prostaglandin analogs market in 2017. This segment is expected to continue its dominance during the forecast period due to its high efficacy and safety profile compared with other types of prostaglandin analogs available in the market.
Product Definition:
A prostaglandin analog is a drug that is similar to the hormone prostaglandin. Prostaglandins are chemicals that are produced by the body and play a role in many important processes, such as blood clotting and inflammation. Prostaglandin analogs are used to treat conditions such as arthritis, asthma, and menstrual cramps. They work by blocking the effects of prostaglandins in the body.
Xalatan:
Xalatan, (1H-xantan-4-one) is a prescription drug used to treat glaucoma. It is an ophthalmic solution that works by increasing the amount of fluid in the eye. The drug has been approved for sale and use in Canada, Mexico, Europe and South Africa; while it is under clinical investigation in the U.S., Australia, Japan and some European countries.
Travatan:
Travatan is a non-steroidal anti-inflammatory drug (NSAID) and is used to treat pain. It works by decreasing the production of prostaglandins which causes pain. Travatan has been approved by the Food and Drug Administration (FDA) for use in adults as well as children over the age of five years for acute painful conditions including bunionitis, osteoarthritis, backpacking, toothache, etc.
Application Insights:
Based on the application, the global prostaglandin analogs market is segmented into clinic, hospital and others. The Others segment includes research institutes and private practices. Clinic held the largest share of over 70% in 2017 owing to increasing number of patients with various disorders demanding effective treatment options.
The Hospital segment is expected to witness significant growth during forecast period due to rising prevalence of chronic diseases such as cancer, heart disease and diabetes that require regular medical checkups and monitoring for proper management along with an increase in number of surgeries being performed daily across the globe which further boosts product demand globally. Moreover, growing awareness about these drugs among hospitals & healthcare providers coupled with easy availability through online pharmacies has boosted their consumption rate continuously since past few years contributing towards market growth significantly.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing number of product launches are some factors responsible for its dominance. Moreover, growing awareness about various treatment options is expected to drive the regional market during the forecast period. Lumigan was approved by FDA in August 2016 as a single-injection therapy for treating glaucoma; however, Xalatan remains dominant due to its off-label use for other applications such as open angle glaucoma and raised intraocular pressure associated with ocular hypertension (high blood pressure within the eye).
Asia Pacific is expected to be one of fastest growing regions over the forecast period owing to rising healthcare expenditure and improving healthcare infrastructure in emerging countries such as China & India. Furthermore, increasing prevalence of ophthalmic disorders coupled with rising disposable income will support growth during this period.
Growth Factors:
- Increasing prevalence of chronic diseases such as asthma, COPD, and other respiratory disorders is expected to drive the demand for prostaglandin analogs over the forecast period.
- Rising geriatric population is also anticipated to boost the market growth as this population is more susceptible to respiratory disorders.
- Growing awareness about the benefits of using prostaglandin analogs over other traditional therapies is projected to propel market growth during the forecast period.
- Technological advancements in drug delivery systems are likely to provide lucrative opportunities for players operating in this market over the next few years. 5) increasing R&D investments by key players will help them introduce new and innovative products in this market, thereby propelling its growth
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostaglandin Analogs Market Research Report
By Type
Xalatan, Travatan, Lumigan, Tafluprost
By Application
Clinic, Hospital, Others
By Companies
Pfizer, Novartis, Merck, Allergan, Newchem S.p.A.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Prostaglandin Analogs Market Report Segments:
The global Prostaglandin Analogs market is segmented on the basis of:
Types
Xalatan, Travatan, Lumigan, Tafluprost
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Novartis
- Merck
- Allergan
- Newchem S.p.A.
Highlights of The Prostaglandin Analogs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Xalatan
- Travatan
- Lumigan
- Tafluprost
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostaglandin Analogs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Prostaglandin analogs are medications that are similar to prostaglandins, but they do not have the same effects on the body. Prostaglandin analogs can be used to treat a variety of conditions, including pain, inflammation, and asthma.
Some of the key players operating in the prostaglandin analogs market are Pfizer, Novartis, Merck, Allergan, Newchem S.p.A..
The prostaglandin analogs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Prostaglandin Analogs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Prostaglandin Analogs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Prostaglandin Analogs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Prostaglandin Analogs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Prostaglandin Analogs Market Size & Forecast, 2018-2028
4.5.1 Prostaglandin Analogs Market Size and Y-o-Y Growth
4.5.2 Prostaglandin Analogs Market Absolute $ Opportunity
Chapter 5 Global Prostaglandin Analogs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Prostaglandin Analogs Market Size Forecast by Type
5.2.1 Xalatan
5.2.2 Travatan
5.2.3 Lumigan
5.2.4 Tafluprost
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Prostaglandin Analogs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Prostaglandin Analogs Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Prostaglandin Analogs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Prostaglandin Analogs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Prostaglandin Analogs Analysis and Forecast
9.1 Introduction
9.2 North America Prostaglandin Analogs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Prostaglandin Analogs Market Size Forecast by Type
9.6.1 Xalatan
9.6.2 Travatan
9.6.3 Lumigan
9.6.4 Tafluprost
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Prostaglandin Analogs Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Prostaglandin Analogs Analysis and Forecast
10.1 Introduction
10.2 Europe Prostaglandin Analogs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Prostaglandin Analogs Market Size Forecast by Type
10.6.1 Xalatan
10.6.2 Travatan
10.6.3 Lumigan
10.6.4 Tafluprost
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Prostaglandin Analogs Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Prostaglandin Analogs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Prostaglandin Analogs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Prostaglandin Analogs Market Size Forecast by Type
11.6.1 Xalatan
11.6.2 Travatan
11.6.3 Lumigan
11.6.4 Tafluprost
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Prostaglandin Analogs Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Prostaglandin Analogs Analysis and Forecast
12.1 Introduction
12.2 Latin America Prostaglandin Analogs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Prostaglandin Analogs Market Size Forecast by Type
12.6.1 Xalatan
12.6.2 Travatan
12.6.3 Lumigan
12.6.4 Tafluprost
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Prostaglandin Analogs Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Prostaglandin Analogs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Prostaglandin Analogs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Prostaglandin Analogs Market Size Forecast by Type
13.6.1 Xalatan
13.6.2 Travatan
13.6.3 Lumigan
13.6.4 Tafluprost
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Prostaglandin Analogs Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Prostaglandin Analogs Market: Competitive Dashboard
14.2 Global Prostaglandin Analogs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Novartis
14.3.3 Merck
14.3.4 Allergan
14.3.5 Newchem S.p.A.
